Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Sees Significant Growth in Short Interest

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 9,061 shares, a growth of 60.0% from the August 31st total of 5,662 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 18,160 shares, the short-interest ratio is currently 0.5 days.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Susquehanna International Group LLP boosted its position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,064 shares of the company’s stock after acquiring an additional 4,046 shares during the quarter. Susquehanna International Group LLP owned 0.17% of Cryo-Cell International worth $45,000 as of its most recent filing with the Securities and Exchange Commission. 10.44% of the stock is owned by institutional investors.

Cryo-Cell International Stock Performance

Cryo-Cell International stock traded down $0.15 during trading on Thursday, hitting $4.05. The company’s stock had a trading volume of 27,839 shares, compared to its average volume of 16,328. The stock’s fifty day moving average is $3.97 and its 200 day moving average is $3.66. Cryo-Cell International has a 1-year low of $2.72 and a 1-year high of $4.90. The stock has a market capitalization of $32.64 million, a price-to-earnings ratio of -13.50 and a beta of 0.47.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share (EPS) for the quarter. The business had revenue of $7.78 million during the quarter.

About Cryo-Cell International

Cryo-Cell International, Inc is a biotechnology and healthcare services company focused on the collection, processing, testing and long-term storage of umbilical cord blood and cord tissue. The company provides families with access to private stem cell banking services intended to preserve potentially valuable biological material for future medical use.

Its services generally include coordinating the collection of cord blood and tissue at birth, transporting specimens to its processing facilities, isolating and cryopreserving stem cells, and maintaining the stored materials under controlled conditions.